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Abstract To investigate the expressions of key markers
in the homologous recombination (HR) pathway and the
correlation with clinicopathological parameters in serous
ovarian cancer (SOC). We analyzed the protein expres-
sion of MRE11, MDC1, ATM, ATR and BRCA1 by
immunohistochemistry (IHC) in 97 SOC samples, and
correlated with clinical parameters including age, tumor
grades, clinical stage, status of menstruation and chemo-
therapy. Low expression of MRE11 and MDC1 was
detected in 14.4 % and 3.1 % of the patient samples,
and negative expression of ATM, ATR and BRCA1 was
found in 11.3 %, 6.3 % and 29.9 % of the patient
samples, respectively. ATR deficiency was significantly
associated with menopause (P=0.025), strong expression
of ATM (P=0.017) and MRE11 (P=0.040) with pre-
menopausal SOC, strong expression of MRE11
(P=0.016) with low tumor grade, and strong expression
of BRCA1 (P=0.015) with early clinical stage. In addi-
tion, low expression of MRE11 was strongly associated
with negativity of ATR (P<0.001) and BRCA1 (P=
0.004) Furthermore, ATR deficiency was associated with
low expression of ATM (P=0.028) and loss expression
of BRCA1 (P=0.009). Our results suggest that reduced
expression or loss of proteins in HR pathway is
associated with SOC development. Abnormality of
MRE11 and BRCA1 are strongly associated with late
clinical stage in SOC patients.
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Introduction
DNA double-strand breaks (DSBs) are particularly haz-
ardous to the cel l since they cause base pair
mismatch,[1] which is strongly associated with cancer
susceptibility. Three mechanisms exist to repair DSBs:
non-homologous end joining (NHEJ), microhomology-
mediated end joining (MMEJ), and homologous recom-
bination (HR).[2] HR-mediated repair requires one ho-
mologous sequence to accurately repair breaks. In con-
t r a s t , MME J r e q u i r e s a 5 – 2 5 b a s e p a i r
microhomologous sequence, whilst NHEJ can function
to directly religate broken ends in the absence of a
homologous template. Moreover, HR repairs DSBs in
the late S and G2 phases of the cell cycle when sister
chromatids are readily available,[3] as opposed to
MMEJ which occurs in S phase and NHEJ in the G0/
G1 and early S phases. Sister chromatids are ideal
templates for repair as they provide identical copies of
the same chromosome. Therefore, HR plays an impor-
tant role in the fidelity of DNA replication,[4] which is
vital to the integrity and stability of the genome.
During an HR repair process, DNA lesions are first
identified and several key repair proteins are recruited.
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These include checkpoint mediator proteins like the
MRN complex (MRE11-NBS1-RAD50) and MDC1.
The MRN complex slows down crossover progression
in mitosis [5] and MDC1 facilitates signal transmission
to downstream proteins.[6, 7] Next, ATM and the
RAD3-related ATR kinase, part of the Phosphatidyl-
Inositol 3 Kinase-like protein Kinase (PIKK) family,
cascade signals which arrest cell cycle progression [8]
and thus allow DNA repair to occur. RAD51 (RAD50
forms MRE11-NSB1-RAD50 complex) also interacts
with breast cancer susceptibility genes 1 and 2
(BRCA1/BRCA2). Finally, ATM and ATR then directly
phosphorylate BRCA1 and BRCA2 to enable activation
of DNA repair [9].
Many reports associate the risk of tumorgenesis with alter-
ations in the HR pathway.[10–12] Aberrations in MDC1 and
MRE11 have been strongly linked to breast carcinogenesis
[13, 14] and also reported in other cancers.[15–17] Mutations
and loss of ATM can contribute to lymphoid malignancies
[18] and familial breast and ovarian cancers.[19, 20]
Hypomorphic mutations of ATR have been linked to BC
and OC development,[21] and mutation and loss of the
BRCA1 gene is widely reported to increase the risk of breast
and ovarian cancer.[22, 23]
Ovarian cancer (OC) is one of the most common hereditary
cancers in women and results in more annual deaths than any
other gynecological malignancy.[24] In recent years, reports
have emerged suggesting that HR deficiency is strongly
linked to the development of OC.[25, 26] 3.7 % deleterious
and 4.8 % missense mutations of ATM have been reported in
familial OC.[20] ATR mutations have been analyzed in famil-
ial breast cancer (BC) and OC, and 23 nucleotide substitution
variants discovered.[27] Mutations in BRCA1/2, the two most
widely studied genes in the HR pathway, have shown a strong
linkage with OC in numerous reports.[28] The majority of the
deaths associated with these mutations were from ovarian
cancer of the serous histological type (SOC).[29] Moreover,
SOC is often detected at an advanced stage, at which time it
has already become highly lethal.[30] To better understand the
alteration of protein expression in HR pathway, and to provide
potential patient selection biomarker for HR inhibitor in SOC,
we have analyzed the immunohistochemical expression of
MRE11,MDC1, ATM, ATR and BRCA1 in 97 serous ovarian




The current study was approved by the ethics committee of
Chinese PLA General Hospital in Beijing. This study
analyzed samples from 97 patients who underwent ovarian
cancer complete resection at from Nov. 2005 to Nov. 2009.
All 97 patients were diagnosed with serous ovarian cancer
(SOC) by 2 qualified pathologists which accounts for more
than 40 % of ovarian malignancies. The median patient age
was 55 years old (range 35–77). Among the 97 cases, 56.7 %
(55/97) of patients had received chemotherapy after surgery
and 68.1 % (66/97) of patients had entered into menopause.
Immunohistochemistry (IHC) Study
All tumor samples were collected immediately after
surgery, fixed in 10 % buffered formalin and then
embedded in paraffin. Four μm-thick tissue sections
were cut for IHC study. The slides were baked at
56ºC for 1 h, followed by de-paraffinized in xylene
and rehydrated through a graded series of ethanol con-
centrations. Antigen retrieval was performed in a pres-
sure cooker for 5 mins using Target Retrieval Solution
(Dako). Endogenous peroxidase activity was blocked by
Peroxidase Blocking Reagent (Dako) for 5 mins. Prima-
ry antibodies (ATM, Epitomics, 1:50; ATR, Santa-cruz
Technology, 1:100; BRCA1, Merck, 1:100; MDC1, Sig-
ma, 1:500; MRE11, Abcam, 1:200) were then applied to
the specimen for 1 h at room temperature, followed by
incubation with labeled polymer-HRP anti rabbit or anti
mouse secondary antibody (Dako) for 30 mins at room
temperature. Thorough rinsing with TBST was per-
formed after incubation with each reagent. The slides
were visualized using DAB substrate-chromagen (Dako)
and washed with deionized water before counterstaining
with haematoxylin (Sigma). The slides were then
dehydrated through a graded series of ethanol concen-
trations, cleared in xylene and coverslipped in DPX
mounting medium. Cases with positive staining of
aforementioned 5 biomarkers in previous study were
used as positive control. Isotype-matched immunoglob-
ulin fraction instead of primary antibodies used in the
experiment served as negative control.
Interpretation of IHC
The intensity of the staining as well as the percentage of
positive cells was recorded. Staining intensity was scored
from 0, 1+, 2+ to 3+ following the criteria: 0, if absence of
staining was observed; 1+, if >10 % of the tumor cells had
weak staining; 2+, if >10 % tumor cells had moderate stain-
ing; and 3+, if >10 % tumor cells had strong staining. Tumors
with 1+, 2+, and 3+ expression were interpreted as
positive and tumors with no expression (0 score) were
interpreted as negative.
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Statistical Analysis
Logistic regression was used to assess the association of
homologous recombination deficiency (HRD) expression
with clinicopathological parameters and P values were com-
puted from log-likelihood ratio test. P values <0.05 were
considered to be statistically significant. Pearson correlation
coefficient method was used to assess the correlation of co-
expression of HRD pathway genes. The data analysis was
performed using R version 2.11.0 on Unix.
Results
Expression of ATM, ATR, MDC1, MRE11 and BRCA1
in SOC
In our SOC samples, negative expression (IHC score ‘0’) of HR
pathway proteinswas at the following rates; ATM11.3% (11/97),
ATR 6.3 % (6/96), and BRCA1 29.9 % (29/97). Low expression
(IHC score ‘0’ and ‘1+’) of MRE11 was detected in 14.4 %
(14/97) and MDC1 in 3.1 % of samples (3/97). (Figs. 1 and 2).
Correlation Between Biomarkers Expression
and Clinicopathological Parameters
Clinical information of the SOC patients recruited into this
study was collected including age, tumor grade, clinical stage,
status of menopause and chemotherapy. Statistical analysis of
IHC data and clinicopathological parameters are shown in
Table 1. Loss of expression of ATM, ATR and BRCA1 and
low expression of MDC1 and MRE11 were not associated
with age, clinical stage, tumor grade and chemotherapy status.
However, loss of ATR expression was significantly correlated
with menopause (P=0.025). Although low or lost expression
of these 5 proteins was not strongly associated with clinico-
pathological parameters, in-depth statistical analysis demon-
strated that strong expression (IHC score ‘3+’) of MRE11
(P=0.016) was significantly associated with low tumor grade
(grade I and II). Furthermore, strong expression of ATM
(P=0.017) and MRE11 (P=0.040), independently, was
strongly associated with pre-menopausal SOC, and finally,
strong expression of BRCA1 (P=0.015) was significantly
associated with early clinical stage (stage I and II). Detailed
analysis results were shown in Table 2.
Overall, 53/96 (55.2 %) SOC cases were identified
with negative IHC expression of at least 1 HR pathway
protein. Combined biomarker analysis results were
shown in Table 3, which indicated that low expression
(IHC score 0 and 1+) of MRE11 was strongly associ-
ated with loss (IHC score 0) of ATR (P<0.001) and
BRCA1 (P=0.004). In addition, deficiency of ATR
(IHC score 0) was strongly associated with low levels
(IHC score 0 and 1+) of ATM (P=0.028) and loss of
expression (IHC score 0) of BRCA1 (P=0.009). Expres-
sion of MDC1 did not show any association with ex-
pression of the other 4 HR pathway proteins.
Discussion
Ovarian cancer is the leading cause of death in gynecological
malignancies. Although platinum-based chemotherapy regi-
mens are widely used to treat OC patients, these are non-
Figure 1 Representative images
of ATM IHC staining with
scoring 0, 1+, 2+ and 3+ in
Chinese SOC. 1a-1d: negative,
weak, moderate and strong
staining of ATM
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specific treatment modalities which can lead to severe side
effects and poor tolerance due to effects on normal tissues.
Recently, several reports have shown that deficiencies in the
levels of key HR pathway proteins are associated with OC.
However, this association has not been fully understood. To
explore this further in a Chinese population, we measured the
expression of key HR pathway proteins (MRE11, MDC1,
ATR, ATM, and BRCA1) and analyzed this data for
Figure 2 Representative images
of IHC staining of MRE11,
MDC1, ATM, ATR and BRCA1
in Chinese SOC. 2a-2b: Low and
strong expression of MRE11; 2c-
2d: Low and strong expression of
MDC1; 2e-2f: negative and
strong staining of ATM; 2G-2H:
negative and strong staining of
ATR; 2i-2j: negative and strong
staining of BRCA1 in different
SOC tumors, respectively.
(Envision, 40 ×)
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associations with clinicopathological parameters in 97 Chi-
nese SOC patients.
MRE11 andMDC1 genetic abnormalities can contribute to
cancer susceptibility.[15–17] Our data shows that the inci-
dence of low expression of MDC1 and MRE11 was 3.1 %
and 14.4 %, respectively. After statistical analysis, we
found strong expression of MRE11 (P=0.016) to be
significantly associated with low tumor grade. Converse-
ly, low levels of MRE11 appear to be associated with
SOC differentiation. Previous reports have indicated ge-
netic MRE11 abnormalities to be linked to development
of various cancers, but protein levels have rarely been
studied in SOC. To our knowledge, this study is the
first to report an association of MRE11 protein expres-
sion with SOC development. Although MDC1 expres-
sion failed to show significant correlations with clinical
stage and menopause, a strong trend was observed be-
tween tumor grade (P=0.09) and chemotherapy treat-
ment status (P=0.06), warranting further investigations
of this protein as a potential SOC prognostic biomarker.
ATM and ATR are important signaling kinases that activate
a complex network of DNA damage response pathways.
These coordinate cell cycle checkpoint and DNA repair
functions.[8] Deficiencies in ATM and ATR can result in
DNA damage sensitivity and cancer predisposition.[10–12]
In the current study, loss of expression of ATM and ATR were
detected in 11.3 % and 6.3 % of patient samples, respectively.
Moreover, statistical analysis showed that loss of expression
of ATR (P=0.025) was significantly correlated with meno-
pause, whilst strong expression of ATM (P=0.017) correlated
with tumors derived from pre-menopausal women.
BRCA1 and BRCA2 protein complexes play critical
roles in halting cell cycle progression and enabling
DNA repair. Mutations in BRCA1 and BRCA2, which
have been reported in various studies, account for 70-
80 % and 15 % of families with a history of OC,
respectively.[31, 32] Women with a familial history of
OC are more likely to develop a deleterious mutation in
BRCA1/2.[28] BRCA1 mutations typically confer a
higher risk of BC and OC than BRCA2 mutations.


































I/II 6 30 0.02 18 18 0.48 31 5 0.27
III 24 37 26 35 47 14
Clinical stage
I/II 2 11 0.21 5 8 0.54 13 0 0.01
III 26 56 39 43 64 18
Menopause
No 5 26 0.04 9 22 0.02 28 3 0.09
Yes 23 41 35 29 49 15
Chemotherapy
No 13 28 0.68 18 23 0.68 34 7 0.68
Yes 15 39 26 28 43 11
Negative staining: IHC score 0; Weak staining: IHC score 1+; Moderate staining: IHC score 2+; Strong staining: IHC score 3+
Table 3 Co-expression analysis amongst individual HR biomarker expression in SOC patients
P-value Mre11 low expression MDC1 low expression ATM low expression ATR negative BRCA1 negative
Mre11 low expression / 0.3768 0.7425 0.0002 0.0044
MDC1 low expression 0.3768 / 0.5722 0.1778 1.0000
ATM low expression 0.7425 0.5722 / 0.0279 1.0000
ATR negative 0.0002 0.1778 0.0279 / 0.0091
BRCA1 negative 0.0044 1.0000 1.0000 0.0091 /
Low expression: IHC score 0 and 1+; Negative: IHC score 0
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Besides OC, deleterious BRCA1 mutations may also
increase a woman’s risk of developing cervical, uterine,
pancreatic, and colon cancer.[33, 34] A recent study
suggested that promoter hypermethylations, somatic mu-
tations, and genomic deletions of BRCA1 might be
responsible for the loss or reduced expression of
BRCA1 protein.[35] Here, we analyzed BRCA1 protein
expression in SOC patients and found a negativity rate
of 29.9 % (29/97). Strong expression was significantly
correlated with early clinical stage (P=0.015). Thus, our
data indicates that loss of BRCA1 protein is associated
with serous ovarian cancer progression.
In the co-expression analysis of all 5 proteins, we found the
following associations: 1) low expression ofMRE11 with loss
of ATR (P<0.001) and BRCA1 (P=0.004) and 2) deficiency
of ATR with low levels of ATM (P=0.028) and expres-
sion loss of BRCA1 (P=0.009). These results showed
that reduced expression of MRE11 can influence the
downstream expression levels of ATR and ATM. Fur-
thermore, the expression level of BRCA1, a direct phos-
phorylation target of ATM, was significantly lower in
patients with ATM loss.
To conclude, by profiling key HR pathway proteins in SOC
patients we have demonstrated that protein expression chang-
es of MRE11 and BRCA1 are strongly associated with serous
ovarian cancer in late clinical stage, suggesting their potential
utility as prognostic tools in the analysis of tumor biopsies or
circulating tumor cells. Moreover, as SOC represents an espe-
cially lethal cancer with limited therapeutic options, we be-
lieve that these association studies further underpin the HR
pathway as a novel area of potential therapeutic intervention
for SOC.
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